ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Two Groups Form to Mark Cancer Act’s 25th Anniversary

May 31, 1996

ONS Continue Growth, Associate Category Defeated Again

May 15, 1987

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

NCI CTEP: Approved Trials For The Month of October

October 28, 2011

In Brief: Basic Science Center Funding Plan Clarified; Janice Feldman Leaves As Chief Of NIH Nursing

February 17, 1989

Susan Horwitz Succeeds Waun Ki Hong As AACR President

April 12, 2002